Dagmar F Hernandez-Suarez1, Hector Núñez-Medina1, Stuart A Scott2, Angel Lopez-Candales1, Jose M Wiley3, Mario J Garcia3, Kyle Melin4, Karid Nieves-Borrero1, Christina Rodriguez-Ruiz1, Lorraine Marshall1, Jorge Duconge5. 1. Medicine Division, University of Puerto Rico School of Medicine, San Juan, Puerto Rico. 2. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 3. Division of Cardiovascular Diseases Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY, USA. 4. Department of Pharmacy Practice, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico. 5. Pharmaceutical Sciences Department, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico.
Abstract
BACKGROUND: Antiplatelet therapy with clopidogrel is recommended to reduce cardiovascular events in patients with peripheral artery disease (PAD); however, clopidogrel efficacy has not been adequately studied in this patient population. Therefore, we aimed to determine the effects of cilostazol therapy on platelet reactivity among PAD patients on clopidogrel. METHODS: We performed a cross-sectional pilot study of 46 Puerto Rican patients diagnosed with PAD. The cohort was divided based on use of clopidogrel and cilostazol (n=24) or clopidogrel alone (n=22). Platelet function was measured ex vivo using the VerifyNow P2Y12 assay. Genomic DNA was extracted from peripheral blood samples using the QIAamp DNA Blood Midi Kit, which was subjected to candidate variant genotyping (CYP2C19, ABCB1, PON1 and P2RY12) using TaqMan quantitative polymerase chain reaction assays. All analyses were performed using SAS version 9.4 (SAS Institute). RESULTS: Among all enrolled patients, 18 (39%) had high on-treatment platelet reactivity (HTPR). The mean platelet reactivity was 207±53 (range, 78-325) with higher P2Y12 reaction units in the non-cilostazol group, 224±45 vs. 191±55 on the cilostazol group (p=0.03). No significant differences were observed in the clinical or genetic variables between the two groups. A multiple regression analysis determined that history of diabetes mellitus (p=0.03), use of cilostazol (p=0.03) and hematocrit (p=0.02) were independent predictors of platelet reactivity. CONCLUSIONS: In Puerto Rican PAD patients on clopidogrel therapy, history of diabetes mellitus, use of cilostazol and hematocrit are independent predictors of platelet reactivity. Adjunctive cilostazol therapy may enhance clopidogrel efficacy among PAD patients with HTPR.
BACKGROUND: Antiplatelet therapy with clopidogrel is recommended to reduce cardiovascular events in patients with peripheral artery disease (PAD); however, clopidogrel efficacy has not been adequately studied in this patient population. Therefore, we aimed to determine the effects of cilostazol therapy on platelet reactivity among PAD patients on clopidogrel. METHODS: We performed a cross-sectional pilot study of 46 Puerto Rican patients diagnosed with PAD. The cohort was divided based on use of clopidogrel and cilostazol (n=24) or clopidogrel alone (n=22). Platelet function was measured ex vivo using the VerifyNow P2Y12 assay. Genomic DNA was extracted from peripheral blood samples using the QIAamp DNA Blood Midi Kit, which was subjected to candidate variant genotyping (CYP2C19, ABCB1, PON1 and P2RY12) using TaqMan quantitative polymerase chain reaction assays. All analyses were performed using SAS version 9.4 (SAS Institute). RESULTS: Among all enrolled patients, 18 (39%) had high on-treatment platelet reactivity (HTPR). The mean platelet reactivity was 207±53 (range, 78-325) with higher P2Y12 reaction units in the non-cilostazol group, 224±45 vs. 191±55 on the cilostazol group (p=0.03). No significant differences were observed in the clinical or genetic variables between the two groups. A multiple regression analysis determined that history of diabetes mellitus (p=0.03), use of cilostazol (p=0.03) and hematocrit (p=0.02) were independent predictors of platelet reactivity. CONCLUSIONS: In Puerto Rican PAD patients on clopidogrel therapy, history of diabetes mellitus, use of cilostazol and hematocrit are independent predictors of platelet reactivity. Adjunctive cilostazol therapy may enhance clopidogrel efficacy among PAD patients with HTPR.
Authors: Marie D Gerhard-Herman; Heather L Gornik; Coletta Barrett; Neal R Barshes; Matthew A Corriere; Douglas E Drachman; Lee A Fleisher; Francis Gerry R Fowkes; Naomi M Hamburg; Scott Kinlay; Robert Lookstein; Sanjay Misra; Leila Mureebe; Jeffrey W Olin; Rajan A G Patel; Judith G Regensteiner; Andres Schanzer; Mehdi H Shishehbor; Kerry J Stewart; Diane Treat-Jacobson; M Eileen Walsh Journal: J Am Coll Cardiol Date: 2016-11-13 Impact factor: 24.094
Authors: T C Leunissen; S M O Peeters Weem; R T Urbanus; H M den Ruijter; F L Moll; F W Asselbergs; G J de Borst Journal: Eur J Vasc Endovasc Surg Date: 2016-05-25 Impact factor: 7.069
Authors: S A Scott; K Sangkuhl; E E Gardner; C M Stein; J-S Hulot; J A Johnson; D M Roden; T E Klein; A R Shuldiner Journal: Clin Pharmacol Ther Date: 2011-06-29 Impact factor: 6.875
Authors: Dagmar F Hernandez-Suarez; Mariana R Botton; Stuart A Scott; Matthew I Tomey; Mario J Garcia; Jose Wiley; Pedro A Villablanca; Kyle Melin; Angel Lopez-Candales; Jessicca Y Renta; Jorge Duconge Journal: Pharmgenomics Pers Med Date: 2018-06-08
Authors: Dagmar F Hernandez-Suarez; Jonnalie C Tomassini-Fernandini; Angelica Cuevas; Anyelis N Rosario-Berrios; Héctor J Nuñez-Medina; Dariana Padilla-Arroyo; Nannette Rivera; Jennifer Liriano; Rocio K Vega-Roman; Jessicca Y Renta; Kyle Melin; Jorge Duconge Journal: Int J Environ Res Public Health Date: 2018-05-30 Impact factor: 3.390